Science

May 5, 2025, 14:17

Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib

Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico , shared a post on X:

“Real-world data, 1323 pts w/EGFRm NSCLC received 1L osimertinib: mOS 28.6 mo (< FLAURA trial)

18% reached 5-y survival; 29% died before 2L, 4% had no further therapy and 19% remained on 1L

Findings support need for optimized 1L combos in high-risk pts.”

Title: Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States

Authors: Joshua K. Sabaria, Helena A. Yub, Parthiv J. Mahadeviac, Yanfang Liud , Levon Demirdjiane, Yen Hua Chend, Xiayi Wangf, Antonio Passaro.

You can read the Full Article on Journal of Thoracic Oncology.

Non-Small Cell Lung Cancer

More posts featuring Oscar Tahuahua.

Antonio Passaro cancer Helena A. Yub Joshua K. Sabaria Levon Demirdjiane Lung cancer NSCLC OncoDaily Oncology Oscar Tahuahua osimertinib Parthiv J. Mahadeviac Xiayi Wangf Yanfang Liud Yen Hua Chend

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care